Korro Bio, Inc. (KRRO) · Oct 22, 2026 · Other events
Preclinical readout — 96% SERPINA1 editing; 95% liver Z-AAT reduction
Korro Bio’s new preclinical results show sustained RNA editing and sharp Z-AAT reduction, strengthening KRRO-111 ahead of a planned 2027 filing.
Korro is a clinical-stage RNA-editing biotech building a liver-focused pipeline: KRRO-121 is moving toward clinical testing, while KRRO-111 is its preclinical AATD program. KRRO-111 was already nominated as a development candidate in May 2026 with roughly 90% in-vivo editing, so the direction was known; this filing adds stronger repeat-dose and liver-specific evidence rather than introducing the program from scratch.
The new data materially deepen the efficacy story. In repeat-dose mouse studies, KRRO-111 reached 96% SERPINA1 mRNA editing, produced M-AAT equal to 93% of circulating AAT, and increased total AAT roughly sixfold versus vehicle at Day 57. 〔0〕 That is more useful than the earlier headline result because it supports sustained, redosable activity rather than only a single-dose effect.
| Preclinical measure | Result | Filing location |
|---|---|---|
| Editing in mouse and human hepatocytes | Up to 98% | KRRO-111 preclinical results |
| Single-dose SERPINA1 editing | Up to 91% | Single-dose mouse studies |
| Repeat-dose SERPINA1 editing | 96% | Repeat-dose studies |
| M-AAT share of circulating AAT | 93% | Repeat-dose studies |
| Total AAT versus vehicle | ~6-fold | Repeat-dose studies |
| Liver Z-AAT reduction | 95% | Repeat-dose studies |
The dual-organ angle is the real strategic improvement. The candidate is not just restoring functional AAT for the lung; it also sharply reduced pathogenic Z-AAT in the liver. 〔1〕 That supports Korro’s claim that the program could address both major disease manifestations, whereas the filing says current augmentation therapy does not adequately address the liver component. 〔2〕
This advances the asset toward the clinic, but does not yet prove a human therapy. The filing still rests on hepatocyte experiments and mouse models, with GLP toxicology ongoing and no clinical evidence that the editing, protein restoration, or Z-AAT reduction will translate into better lung or liver outcomes. The “best-in-class” label is also management’s positioning, not a head-to-head result. The practical change is therefore lower preclinical uncertainty and a clearer path to an expected regulatory submission, not clinical validation.
Bottom line: This is a meaningful upgrade to an already-public KRRO-111 story: the repeat-dose data show durable editing plus liver-disease relevance. It strengthens the case for entering the clinic, while the major value test remains human safety and efficacy.
Regulatory submission for KRRO-111, first half of 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!